Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb:80:102283.
doi: 10.1016/j.coi.2023.102283. Epub 2023 Jan 28.

Immune checkpoint receptors in autoimmunity

Affiliations
Review

Immune checkpoint receptors in autoimmunity

Kelly P Burke et al. Curr Opin Immunol. 2023 Feb.

Abstract

Immune checkpoint receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell immunoglobulin and ITIM domain (TIGIT) have distinct and overlapping inhibitory functions that regulate Tcell activation, differentiation, and function. These inhibitory receptors also mediate tolerance, and dysregulation of these receptors can result in a breach of tolerance and the development of autoimmune syndromes. Similarly, antibody blockade of immune checkpoint receptors or their ligands for cancer immunotherapy may trigger a spectrum of organ inflammation that resembles autoimmunity, termed immune-related adverse events (irAE). In this review, we discuss recent advances in the regulation of autoimmunity by immune checkpoint receptors. We highlight coordinated gene expression programs linking checkpoint receptors, heterogeneity within autoreactive T-cell populations, parallels between irAE and autoimmunity, and bidirectional functional interactions between immune checkpoint receptors and their ligands.

Keywords: Autoimmunity; Checkpoint receptor ligand; Checkpoint receptors; Immune related adverse event (irAE); PD-1; PD-L1; T cell tolerance.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Sharpe AH, Pauken KE: The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 2017. - PubMed
    1. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T: Establishment of NOD-Pdcd1−/− mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A 2005, 102:11823–11828. - PMC - PubMed
    1. Bettini M, Szymczak-Workman AL, Forbes K, Castellaw AH, Selby M, Pan X, Drake CG, Korman AJ, Vignali DA: Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol 2011, 187:3493–3498. - PMC - PubMed
    1. Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ: CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood 2016, 128:1037–1042. - PMC - PubMed
    1. Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N: PD-1/PD-L and autoimmunity: A growing relationship. Cell Immunol 2016, 310:27–41. - PubMed

Publication types